Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • A Drug-Sensitized Yeast Platform for Sensitive mTOR Inhibito

    2026-05-06

    A Drug-Sensitized Yeast Platform for Sensitive mTOR Inhibitor Discovery

    Study Background and Research Question

    Mechanistic target of rapamycin (mTOR) is a conserved serine/threonine kinase regulating cell growth, proliferation, and survival. Pharmacological inhibition of mTOR, notably by rapamycin, is well-established to extend lifespan and health span across model organisms, but rapamycin’s off-target effects and immunosuppressive properties limit its translational scope. There is a pressing need for new mTOR inhibitors with distinct profiles for clinical and research applications. Saccharomyces cerevisiae (budding yeast) has historically been pivotal for mTOR pathway studies, owing to its genetic tractability and conserved TOR signaling. However, robust screening for TOR inhibitors is challenged by yeast’s intrinsic drug efflux mechanisms and the presence of functionally redundant TOR paralogs (TOR1 and TOR2). The central research question in the reference study is: can a genetically engineered, drug-sensitized yeast platform be developed to effectively and sensitively identify both canonical and novel mTOR inhibitors for use in geroprotection and oncology research (GeroScience 2025)?

    Key Innovation from the Reference Study

    The study introduces a refined yeast-based screening system that combines targeted mutations in TOR pathway genes with deletion of 12 drug efflux genes, creating a highly drug-sensitive background. This innovation markedly increases the sensitivity of the assay to known mTOR inhibitors, enabling detection of inhibitory activity at nanomolar concentrations—orders of magnitude lower than required in wild-type strains. Such heightened sensitivity accelerates drug discovery efforts and allows for the identification of mTOR inhibitors that may be missed by traditional platforms (GeroScience 2025).

    Methods and Experimental Design Insights

    The researchers generated a panel of yeast strains with genetic perturbations in the TOR pathway (e.g., tor1Δ, tor1-1 allele) and in FPR1, the FK506-sensitive proline rotamase implicated in rapamycin binding. These were further engineered by deleting 12 genes associated with drug efflux, resulting in a background hypersensitive to small molecule inhibitors. Both wild-type and drug-sensitized strains were exposed to known mTOR inhibitors (Torin1, GSK2126458, AZD8055) as well as compounds with reported or hypothesized mTOR activity (e.g., caffeine analogs, aminophylline, canagliflozin, withaferin A, nebivolol, isoliquiritigenin, ganoderic acid A, taurine). Growth inhibition was quantitatively assessed, and the dependency on TOR1 function was validated genetically. Assay sensitivity was compared by determining the minimal concentrations required to observe TOR1-dependent growth inhibition across strain backgrounds (GeroScience 2025).

    Protocol Parameters

    • assay | Concentration of Torin1 required for TOR1-dependent inhibition | 25 μM in wild-type, 100 nM in drug-sensitized yeast | Demonstrates 200-fold increased sensitivity in engineered strains | paper
    • assay | Concentration of GSK2126458 (omipalisib) required for effect | 100 μM in wild-type, 500 nM in drug-sensitized yeast | 250-fold sensitivity enhancement | paper
    • assay | AZD8055 concentration for selective TOR1-dependent inhibition | 100 μM in drug-sensitive strain, none in wild-type | Reveals activity otherwise undetectable in standard backgrounds | paper
    • assay | Negative screening for canagliflozin and related agents | 10–100 μM range | No evidence of TOR pathway inhibition | paper
    • workflow_recommendation | For SGLT2 inhibitor controls (e.g., canagliflozin), start with 10–100 μM in yeast or mammalian cell models | Applicability in glucose homeostasis or renal transport studies, not mTOR | Ensures biological pathway specificity | workflow_recommendation

    Core Findings and Why They Matter

    The engineered drug-sensitized yeast system dramatically increases assay sensitivity for mTOR inhibitor identification. Torin1 and GSK2126458, two structurally distinct mTOR inhibitors, inhibit yeast growth at nanomolar concentrations in the new platform, compared to micromolar concentrations in wild-type yeast (GeroScience 2025). The platform also distinguishes TOR1-dependent effects of compounds previously thought to be non-selective, such as aminophylline. Of particular relevance to metabolic research, compounds like canagliflozin, nebivolol, and isoliquiritigenin did not inhibit TOR signaling at concentrations up to 100 μM, providing direct evidence against their involvement in mTOR modulation in this model. This specificity is crucial for researchers aiming to dissect signaling networks in aging, diabetes, and oncology, allowing better experimental targeting and reducing confounding off-target effects.

    Comparison with Existing Internal Articles

    Several internal review articles have addressed the mechanistic selectivity of canagliflozin (hemihydrate) in metabolic disorder and glucose metabolism research. For example, "Canagliflozin (Hemihydrate): Precise SGLT2 Inhibitor for ..." (miglitol.com) and "Rethinking SGLT2 Inhibitor Strategy: Mechanistic Insights..." (miglitol.com) both emphasize that canagliflozin hemihydrate is a high-purity, small molecule SGLT2 inhibitor with pathway specificity for inhibiting renal glucose reabsorption, not mTOR signaling. The new findings from GeroScience (2025) provide direct experimental evidence supporting these internal analyses, confirming that canagliflozin does not exert off-target effects on mTOR in yeast-based assays. This alignment helps guide researchers in designing experiments that focus on glucose homeostasis pathways rather than unintended mTOR modulation. For broader context, "Canagliflozin Hemihydrate: Expanding the Landscape of SGL..." (gsk1904529a.com) draws similar distinctions between mTOR and SGLT2 inhibitor mechanisms, now experimentally substantiated by the latest yeast platform data.

    Limitations and Transferability

    While the drug-sensitized yeast system offers a robust and highly sensitive tool for early-phase mTOR inhibitor screening, several limitations should be noted. The platform relies on yeast TOR signaling, which, although highly conserved, does not fully recapitulate the complexity of mammalian mTORC1 and mTORC2 functions. Additionally, the deletion of multiple drug efflux pumps may alter yeast physiology in ways that do not fully reflect mammalian pharmacokinetics or resistance mechanisms. Negative results in yeast (such as absence of mTOR inhibition by canagliflozin) should be interpreted in the context of subsequent validation in mammalian or humanized systems. Nonetheless, the platform provides an effective first-pass filter for specificity and off-target profiling (GeroScience 2025).

    Research Support Resources

    For researchers aiming to dissect glucose metabolism, renal glucose reabsorption, or diabetes mellitus pathways without mTOR confounding, Canagliflozin (hemihydrate) (SKU C6434) is available from APExBIO, offering high-purity SGLT2 inhibition suitable for mechanistic and translational studies. Its documented absence of mTOR pathway effects in sensitive yeast and mammalian models supports its use as a pathway-selective tool compound in advanced glucose homeostasis research (miglitol.com; GeroScience 2025).